A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma ("The ATG Study").
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety based on adverse event reports and clinical laboratory findings
During protocol therapy prior to the start of and during each cycle and up to 30 days after last dose of protocol therapy
Anna C Pavlick, MD
NYU MEDICAL CENTER
United States: Food and Drug Administration
|New York University Cancer Center||New York, New York 10016|